Miv-cel Shows Durable, Significant Benefit for Stiff Person
In a single-arm registrational Phase 2 trial (KYSA-8) in 26 patients with stiff person syndrome (SPS), a one-time infusion...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
In a single-arm registrational Phase 2 trial (KYSA-8) in 26 patients with stiff person syndrome (SPS), a one-time infusion...
Intelligent Bio Solutions has initiated a validation study to cut the analysis time of its Intelligent Fingerprinting Drug Screening...
In a non-human primate chronic cough model, Addex’s orally available GABAB positive allosteric modulator cut citric acid–induced cough frequency...
Prelude Therapeutics priced a $90 million gross underwritten equity offering, issuing 18,018,014 shares at $4.44 and pre-funded warrants for...
ctDNA from 123 atebimetinib-treated patients showed rare emergent MAPK pathway alterations and minimal early molecular evolution, with resistance patterns...
ORR signals dominated Junshi Biosciences’ AACR update: in first‑line metastatic colorectal cancer, JS207 plus XELOX produced a 71.0% objective...
In a retrospective cohort of 28 heavily pretreated metastatic triple-negative breast cancer patients, leronlimab exposure was associated with induction...
Trevi Therapeutics has closed a public offering of 13.34 million shares at $13.00 per share for gross proceeds of...
The White House issued an Executive Order aimed at accelerating development and access for psychedelic-based treatments, outlining potential prioritization...
In early Phase 1 dose escalation, BBOT’s pan-KRAS inhibitor BBO-11818 produced a confirmed partial response in pancreatic ductal adenocarcinoma...